Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer

Brun,Jean-Luc; Cortez,Annie; Lesieur,Bénédicte; Uzan,Serge; Rouzier,Roman; Daraï,Emile

doi:10.3892/or.2011.1608

Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer

Authors:
- Jean-Luc Brun
- Annie Cortez
- Bénédicte Lesieur
- Serge Uzan
- Roman Rouzier
- Emile Daraï
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Hôpital Pellegrin, Place Amélie Raba Léon, F-33076 Bordeaux, France
Published online on: December 22, 2011 https://doi.org/10.3892/or.2011.1608
Pages: 1049-1057

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in tumor invasion, but their prognostic significance is still under discussion. We set out to analyze the epithelial and stromal expression of MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 in advanced epithelial ovarian cancers and to assess their prognostic value. A tissue microarray of malignant ovarian tumors from 69 patients was constructed. Immunostaining results were scored using the HSCORE and assessed by univariate analysis with Bonferroni correction and classical multidimensional scaling (CMDS). Kaplan-Meier survival curves calculated with regard to patient and tumor characteristics were compared by the log-rank test. Patients treated by primary surgery (n=43) had a higher tumor size and a trend toward higher epithelial MMP and TIMP expression than those treated by interval surgery (n=26). Optimal cytoreduction (residue ≤1 cm) was obtained in 27 and 18 patients, respectively. Clinical and histological characteristics were not different in patients with optimal cytoreduction and those with suboptimal cytoreduction. The expression of epithelial MMP-9 (P=0.002) and TIMP-2 (P=0.026) were higher in the latter group. CMDS failed to demonstrate any influence of MMP and TIMP expression with regard to cytoreduction outcome. MMP and TIMP expression did not influence survival. Their prognostic values were outweighed by histological type, lymph node involvement and cytoreduction. Standard statistical analysis adjusted after Bonferroni correction and CMDS reduced the relevance of MMPs and TIMPs in the prognosis of patients with advanced ovarian cancer.

View Figures

View References

1	Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S and Anacker J: Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer. 13:5532010.PubMed/NCBI
2	Wu X, Li H, Kang L, Wang W and Shan B: Activated matrix metalloproteinase-2: a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol. 84:126–134. 2002. View Article : Google Scholar : PubMed/NCBI
3	Planagumà J, Liljeström M, Alameda F, et al: Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol. 42:57–67. 2011.PubMed/NCBI
4	Wang FQ, So J, Reierstad S and Fishman DA: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 114:19–31. 2005. View Article : Google Scholar : PubMed/NCBI
5	Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG and Stack MS: Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res. 69:7121–7129. 2009. View Article : Google Scholar : PubMed/NCBI
6	Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS and Mok SC: Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 77:369–376. 2000. View Article : Google Scholar : PubMed/NCBI
7	Kim TJ, Rho SB, Choi YL, et al: High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol. 37:906–913. 2006. View Article : Google Scholar : PubMed/NCBI
8	Davidson B, Goldberg I, Gotlieb WH, et al: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis. 17:799–808. 1999. View Article : Google Scholar : PubMed/NCBI
9	Davidson B, Reich R, Berner A, et al: Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer. 37:2040–2049. 2001. View Article : Google Scholar : PubMed/NCBI
10	Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM and Reich R: The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol. 187:39–45. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 12:1707–1714. 2006. View Article : Google Scholar : PubMed/NCBI
12	Périgny M, Bairati I, Harvey I, et al: Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol. 129:226–231. 2008.PubMed/NCBI
13	Rauvala M, Puistola U and Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol. 99:656–663. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sillanpää SM, Anttila MA, Voutilainen KA, et al: Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin. Int J Cancer. 119:1792–1799. 2006.PubMed/NCBI
15	Sillanpää S, Anttila M, Suhonen K, et al: Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol. 28:280–289. 2007.PubMed/NCBI
16	Sillanpää S, Anttila M, Voutilainen K, et al: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 104:296–303. 2007.PubMed/NCBI
17	Benedet JL, Bender H, Jones H III, Ngan HYS and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 70:209–262. 2000. View Article : Google Scholar : PubMed/NCBI
18	Brun JL, Cortez A, Commo F, Uzan S, Rouzier R and Daraï E: Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol. 33:1239–1246. 2008.PubMed/NCBI
19	Skacel M, Skilton B, Pettay JD and Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimen: a review of the method with validation data. Appl Immunohistochem Mol Morphol. 10:1–6. 2002. View Article : Google Scholar : PubMed/NCBI
20	Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P and Darai E: Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expressions in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol. 17:637–645. 2006. View Article : Google Scholar
21	Budwit-Novotny DA, McCarty KS, Cox EB, et al: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 46:5419–5425. 1986.PubMed/NCBI
22	Bland JM and Altman DG: Multiple significance tests: the Bonferroni method. BMJ. 310:1701995. View Article : Google Scholar : PubMed/NCBI
23	Cai KQ, Yang WL, Capo-Chichi CD, et al: Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinogen. 46:130–143. 2007. View Article : Google Scholar : PubMed/NCBI
24	Shigemasa K, Tanimoto H, Sakata K, et al: Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol. 17:52–58. 2000. View Article : Google Scholar : PubMed/NCBI
25	Afzal S, Lalani EN, Poulsom R, et al: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol. 29:155–165. 1998. View Article : Google Scholar : PubMed/NCBI
26	Sakata K, Shigemasa K, Nagai N and Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 17:673–681. 2000.PubMed/NCBI
27	Määttä M, Santala M, Soini Y, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumor Biol. 25:188–192. 2004.PubMed/NCBI
28	Behrens P, Rothe M, Florin A, Wellman A and Wernert N: Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med. 8:149–154. 2001.PubMed/NCBI
29	Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U and Uray M: Prognostic value of matrix metalloproteinase-9 (gelatinase B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 24:417–420. 2003.PubMed/NCBI
30	Adley BP, Gleason KJ, Yang XJ and Stack MS: Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol. 112:319–324. 2009. View Article : Google Scholar : PubMed/NCBI
31	Demeter A, Sziller I, Csapo Z, et al: Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res. 25:2885–2889. 2005.PubMed/NCBI
32	Lengyel E, Schmalfeldt B, Konik E, et al: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 82:291–298. 2001. View Article : Google Scholar : PubMed/NCBI
33	Lin YG, Han LY, Kamat AA, et al: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 109:332–334. 2007. View Article : Google Scholar : PubMed/NCBI
34	Lin CK, Chao TK, Yu CP, Yu MH and Jin JS: The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 117:162–175. 2009. View Article : Google Scholar : PubMed/NCBI